Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SAR443765 in Healthy Adult Participants and of a Single Dose of SAR443765 in Participants With Mild-to-moderate Asthma

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SAR443765 in Healthy Adult Participants and of a Single Dose of SAR443765 in Participants With Mild-to-moderate Asthma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lunsekimig (Primary) ; Levosalbutamol; Salbutamol
  • Indications Asthma
  • Focus Adverse reactions; First in man
  • Sponsors Sanofi

Most Recent Events

  • 22 May 2024 Results verifying the hypothesis that SAR443765 modulates signaling pathways associated with TSLP, IL-13 and FeNO-high asthma both in the periphery and the respiratory tract, single-cell (sc) RNAseq analysis was performed, presented at the 120th International Conference of the American Thoracic Society
  • 24 May 2023 Results presented at the 119th International Conference of the American Thoracic Society
  • 05 May 2023 According to a Sanofi media release, data from this trial will be presented during the Breaking News: 2023 Clinical Trial Results in Pulmonary Medicine session.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top